WASHINGTON -- Adolescents treated with a low dose oral contraceptive reported a significantly greater reduction in pain as sociated with dysmenorrhea than did their counter-parts who received a placebo in a small study. Dr. Anne Davis reported at the annual meeting of the Association of Reproductive Health Professionals.
The study is the first randomized, controlled trial of low-dose OCs to treat dysmenorrhea in a teen population, noted Dr. Davis, a consultant for Wyeth Pharmaccuticals Inc., which markets Alesse, the OC used in the study.
Low-dose OCs have proven effective in treating amenorrhea in adolescent girls, so the investigators hypothesized that these agents would be similarly successful in treating dysmenorrhea, according to Dr. Davis, who is an ob.gyn, in the division of prevention and ambulatory care at Columbia University Medical Center, New York.
A total of 76 girls, mean age 16 years, were randomized to receive either three cycles of treatment with a combination of 100 [micro]g levonorgestrel plus 20 [micro]g ethinyl estradiol (Alesse) or placebo.
Overall, 57% of the girls reported severe dysmenorrhea at baseline. Results were assessed based on phone interviews conducted after each cycle.
At the end of the 3 months, mean scores on the Moos Menstrual Distress Questionnaire (MMDQ) pain subscale dropped significantly more in the OC group compared with the placebo group. Both groups had significant decreases in pain from baseline, however, ranging from 11.1 to 2.8 in the OC group and from 11.8 to 5.5 in the placebo group.
In addition, 61% of the girls in the OC group reported using no analgesics by the third cycle of the study, compared with 36% in the placebo group. Dr. Davis reported.
The study was funded by a grant from the National Institute of Child Health and Human Development.
COPYRIGHT 2004 International Medical News Group
COPYRIGHT 2004 Gale Group